We publish no single base value for Revvity. Our valuation methods put it between $80.26 and $89.40 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
| Method | Value | vs price | Basis |
|---|---|---|---|
| Discounted cash flow | $89.40 | -43.1% | free cash flow $591.62m, growth 4.3% for 5 years, then fading to 3% over 5 more, discounted at 9.59%; stress floor $60.51 |
| Exit multiple (P/E) | $80.26 | -48.9% | earnings per share $5.44 valued at 19.37× (the stock's own median P/E) in 5 years, discounted back |
| Sum of the parts | — | — | no sum of the parts: this run holds no segment disclosure for the name |
| Price to sales | — | — | not reached: the cash-flow or earnings methods produced an anchor, so this fallback was not run |
| Tangible book | — | — | used only for lenders, where book value is the business |
| Price to FFO (REITs) | — | — | used only for REITs |
Each working is rebuilt by code from the valuation's own figures and checked against the published value.
The discount rate:
| Risk-free rate | 5.13% (10-year US Treasury yield) |
| Company's own beta | 1.08 (5 years of monthly returns against the S&P 500; standard error 0.25) |
| Peer beta | 0.77 (median of 15 S&P 500 Health Care Equipment companies) |
| Blend of own and peers | 0.98 (69% own, 31% peers, weighted by how precisely the company's own beta is measured) |
| Adjusted beta | 0.99 (0.67 × 0.98 + 0.33, pulled toward the market's 1.0) |
| Equity risk premium | 4.5% |
| Discount rate = risk-free + adjusted beta × premium | 9.59% |
Free cash flow grows 4.30% a year for 5 years, then fades in equal steps toward 3% over 5 more; each year is discounted by 1 ÷ (1 + rate)^year:
| Year | Growth | Free cash flow | Discount factor | Present value |
|---|---|---|---|---|
| Now | — | $591.62m | — | — |
| Year 1 | 4.30% | $617.05m | 0.9125 | $563.08m |
| Year 2 | 4.30% | $643.59m | 0.8327 | $535.93m |
| Year 3 | 4.30% | $671.26m | 0.7599 | $510.08m |
| Year 4 | 4.30% | $700.13m | 0.6934 | $485.48m |
| Year 5 | 4.30% | $730.23m | 0.6328 | $462.07m |
| Year 6 | 4.08% | $760.05m | 0.5774 | $438.87m |
| Year 7 | 3.87% | $789.44m | 0.5269 | $415.97m |
| Year 8 | 3.65% | $818.25m | 0.4808 | $393.44m |
| Year 9 | 3.43% | $846.35m | 0.4388 | $371.35m |
| Year 10 | 3.22% | $873.57m | 0.4004 | $349.77m |
| Terminal value = year-10 cash flow × (1 + 3%) ÷ (9.59% − 3%) | $13.66bn |
| Terminal value in today's money | $5.47bn |
| Present value of years 1–10 | $4.53bn |
| Total present value | $10.00bn |
| Shares outstanding | 111.83m |
| Value per share = total ÷ shares | $89.40 |
How the DCF value moves with the discount rate and the starting growth (the middle cell is the published value):
| Discount rate | Growth -0.7% | Growth 4.3% | Growth 9.3% |
|---|---|---|---|
| 8.59% | $77.73 | $105.64 | — |
| 9.59% | $66.37 | $89.40 | — |
| 10.59% | $57.98 | $77.45 | — |
The same DCF at each beta, starting growth unchanged:
| Beta | Value | Discount rate | DCF value |
|---|---|---|---|
| Company's own beta | 1.08 | 9.99% | $84.15 |
| Peer beta | 0.77 | 8.59% | $105.45 |
| Adjusted beta (used) | 0.99 | 9.59% | $89.40 |
Earnings per share grow on the same fading path as the DCF:
| Year | Growth | Earnings per share |
|---|---|---|
| Now | — | $5.44 |
| Year 1 | 4.30% | $5.67 |
| Year 2 | 3.97% | $5.90 |
| Year 3 | 3.73% | $6.12 |
| Year 4 | 3.55% | $6.33 |
| Year 5 | 3.41% | $6.55 |
| Earnings per share in year 5 | $6.55 |
| Exit P/E (the stock's own median P/E) | 19.37× |
| Value in 5 years = earnings × P/E | $126.84 |
| Discounted at 9.59% over 5 years: ÷ 1.5804 | $80.26 |
We publish no single base value for Revvity. Our valuation methods put it between $80.26 and $89.40 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
One-year price simulation: a 10% chance the price is below $91.33 and a 10% chance it is above $271.51 in a year; a 50% chance it is higher than today's $157.02, from 42.29% volatility. The simulation assumes the price drifts up at our discount rate of 9.59% a year.
At $157.02 the price implies free cash flow growing 13.9% a year for five years and then fading toward 3% over five more; its revenue has grown 4.3%.
| Week | Price | Base value |
|---|---|---|
| 2 Oct 2026 | $151.53 | — |
| 9 Oct 2026 | $154.18 | — |
| 16 Oct 2026 | $152.64 | — |
| 23 Oct 2026 | $158.77 | — |
| 30 Oct 2026 | $157.00 | — |
| 6 Nov 2026 | $155.11 | — |
| 12 Nov 2026 | $157.02 | — |
Data as of 12 Nov 2026; financials to 30 Sep 2026. Sources: company filings via EODHD, SEC EDGAR, US Treasury. How these values are computed. Not investment advice.
Run a full Desk Run on RVTY · Revvity company page · Call and put prices